Cancer Therapy Advisor App Download
Free Cancer Therapy Advisor App download for oncology news, cancer drug information, treatment regimens and more. Free on the App Store, Google Play and Amazon.
Free Cancer Therapy Advisor App download for oncology news, cancer drug information, treatment regimens and more. Free on the App Store, Google Play and Amazon.
Older adults with PD-L1+ NSCLC may fare better if they receive immunotherapy rather than chemoimmunotherapy, data suggest.
Stereotactic ablative body radiotherapy may be an effective treatment strategy for patients with inoperable or high-risk primary renal cell carcinoma, according to researchers.
Penpulimab has demonstrated activity in a phase 1b/2 trial of patients with advanced solid tumors.
Women with BRCA1/2 sequence variations have a lower risk of death if they undergo bilateral oophorectomy, data suggest.
Adding durvalumab to first-line chemoradiotherapy did not improve outcomes in patients with stage III NSCLC in the PACIFIC-2 trial.
Recent declines in opioid prescribing may have resulted in inadequate pain control for cancer patients.
Updated data from the DeLLphi-300 study suggest that tarlatamab can produce durable responses in patients with previously treated SCLC.
Twice-daily radiation should remain the standard of care for patients with LS-SCLC receiving concurrent chemoradiation, according to researchers.
Data suggest that first-line osimertinib and chemotherapy can improve long-term outcomes over osimertinib alone in EGFR-mutant advanced NSCLC.
Data suggest that first-line osimertinib and chemotherapy can improve long-term outcomes over osimertinib alone in EGFR-mutant advanced NSCLC.